Ligand-targeted liposomes for cancer treatment.
Selective targeting of ligand-targeted liposomes containing anticancer drugs or therapeutic genes to cell surface receptors expressed on cancer cells is a recognized strategy for improving the therapeutic effectiveness of conventional chemotherapeutics or gene therapeutics. Some recent advances in the field of ligand-targeted liposomes for the treatment of cancer are summarized including: selection criteria for the receptors to be targeted, choice of targeting ligands and choice of encapsulated therapeutics. Targeting of liposomes to solid tumors, versus angiogenic endothelial cells versus vascular targets is discussed. Ligand-targeted liposomes have shown considerable promise in preclinical xenograft models and are poised for clinical development.
Sapra
Puja
P
Immunomedics, Inc., Morris Plains, NJ 07940, USA.
Tyagi
Pradeep
P
Allen
Theresa M
TM
D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000627:therapeutic use*; D004337:Drug Carriers; D016503:Drug Delivery Systems; D019008:Drug Resistance, Neoplasm; D015316:Genetic Therapy / Q000379:methods; D006801:Humans; D008024:Ligands; D008081:Liposomes; D009369:Neoplasms / Q000188:drug therapy* / Q000628:therapy
D000970:Antineoplastic Agents; D004337:Drug Carriers; D008024:Ligands; D008081:Liposomes